Table 2 Demographics of the study population at baseline
Haemodialysis n (%) or Median (IQR) | Haemodiafiltration n (%) or Median (IQR) | p | |
|---|---|---|---|
Number | 106 | 71 | |
Age | |||
5–10 | 22 (20.8) | 15 (21) | 0.78 |
10–15 | 37 (34.9) | 27 (38) | |
15–20 | 47 (44.3) | 29 (41) | |
Gender (female) | 45 (42) | 43 (60) | 0.03 |
Ethnicity | |||
Caucasian / Asian / African /other | 66 / 21 / 9 /’10 | 46 / 17 / 5 / 3 | 0.42 |
Underlying renal diagnosis | |||
Dysplasia | 54 (51) | 32 (45) | 0.76 |
Glomerulonephritis | 25 (24) | 19 (26) | |
Cystic kidney disease | 4 (4) | 5 (7) | |
Other | 17 (15) | 11 (16) | |
Unknown | 6 (6) | 4 (6) | |
Presence of comorbidities | 0.81 | ||
Impaired cognitive development | 22 (21) | 14 (20) | |
Impaired motor development | 11 (10) | 6 (8) | |
Ocular or hearing abnormalities | 18 (17) | 11 (15) | |
Other abnormalities | 25 (24) | 13 (18) | |
Confirmed genetic disorder | 17 (16) | 12 (17) | |
Previous dialysis | 35 (33) | 34 (48) | 0.07 |
Modality (PD / HD / both) | 22 / 8 / 5 | 14 / 14 / 6 | 0.17 |
Cumulative time on dialysis before study (months) | 24 (10, 52) | 28 (16, 45) | 0.92 |
Previous transplant | 18 (17) | 21 (29) | 0.06 |
Time with functioning graft (mts) | 33 (16, 96) | 66 (12, 114) | 0.96 |
Residual urine volume (ml/day) | |||
< 200 / 200–500 / > 500 | 66 (62) / 22 (21) / 18 (17) | 44 (62) / 13 (18) / 14(20) | 0.85 |
Details of dialysis therapy | |||
Filter | |||
High flux / Mid flux / Low flux | 67 (63) / 24 (23) / 15(14) | 71 (100) | < 0.00001 |
Dialysis water qualitya | |||
Pure vs ultrapure | 51 (48) / 55 (52) | 71 (100) | < 0.00001 |
Vascular accessb | |||
AVF / CVL / AVG | 34 (33) / 71 (67) / 1 (1) | 27 (38) / 42 (59) / 2(3) | 0.34 |
Blood flow /m2 body surface area | 182 (148, 215) | 174 (144, 205) | 0.40 |
Dialysate sodium | |||
≤ 138 mmol/l | 76 (72) | 49 (69) | 0.79 |
> 138 mmol/l | 30 (28) | 22 (31) | |
Dialysate bicarbonate | |||
32–35 mMol/L | 68 (64) | 42 (59) | 0.48 |
36–42 mMol/L | 38 (36) | 29 (41) | |